Lacunary Selenotungstate Serves as a Therapeutic Agent for Uranium Intake

The internal contamination of uranium poses severe health risks to both professionals and the public in case of nuclear accidents due to its chemo- and radiotoxicity. Although chelation therapy has been considered the only practical treatment in emergencies, current clinical chelators show only limited efficacy for uranium. Herein, a recently designed lacunary selenotungstate polyoxometalate (Se6W45) was demonstrated as an effective therapeutic agent. In this construct, the open site in Se6W45 provides a suitable uranium binding environment, resulting in the selective removal of uranium from kidneys (85.87%) and femurs (39.81%) with an extremely low ligand/metal ratio of only 4:1. The redox active sites in Se6W45, primarily the incorporated selenium, were able to reduce the intracellular reactive oxygen species (ROS) to normal levels in NRK-52E cells exposed to uranium. This approach overcomes the disadvantages of the excessive use of current chelating ligands in the range from 100- to 1000-folds, avoiding the consequential depletion of heterogeneous cations, dysfunction of proteins, and/or acid–base imbalance. More importantly, it provides a synergistic antidotal therapy for uranium in reducing radiation damage and chemical toxicity.